환자 정보 전단
NIDEM- Consumer Medicine Information
Page 1 of 4
Nidem
gliclazide
CONSUMER MEDICINE INFORMATION (CMI)
WHAT IS IN THIS LEAFLET
This leaflet answers some common
questions about NIDEM.
It does not contain all of the
available information. It does not
take the place of talking to your
doctor, pharmacist or diabetes
educator.
All medicines have benefits and
risks. Your doctor has weighed the
risks of you taking NIDEM against
the benefits they expect it will have
for you.
TALK TO YOUR DOCTOR, PHARMACIST
OR DIABETES EDUCATOR IF YOU
HAVE ANY CONCERNS ABOUT TAKING
THIS MEDICINE.
KEEP THIS LEAFLET WITH YOUR
MEDICINE.
You may need to read it again.
WHAT NIDEM IS USED FOR
NIDEM is used to control blood
glucose in people with Type 2
diabetes mellitus. This type of
diabetes is also called non-insulin
dependent diabetes mellitus
(NIDDM) or maturity onset
diabetes.
NIDEM is used when diet and
exercise are not enough to control
your blood glucose levels. It can be
used alone, or in combination with
other medicines for treating
diabetes.
NIDEM is available only with a
doctor's prescription.
HOW NIDEM WORKS
NIDEM belongs to a group of
medicines called sulphonylureas.
These medicines lower blood
glucose by increasing the amount of
insulin produced by your pancreas.
If your blood glucose is not properly
controlled, you may experience
hypoglycaemia (low blood glucose)
or hyperglycaemia (high blood
glucose).
HYPOGLYCAEMIA
Hypoglycaemia (low blood glucose)
can occur suddenly. Signs may
include:
• weakness, trembling or shaking
• sweating
• lightheadedness, dizziness,
headache or lack of concentration
• irritability, tearfulness or
전체 문서 읽기
제품 특성 요약
NIDEM- Product Information
Page 1 of 5
Nidem
PRODUCT INFORMATION
NAME OF THE MEDICINE
Gliclazide. The chemical name for gliclazide is 1-(3-azabicyclo[3.3.0] oct- 3-yl)-3-para-
tolylsulfonylurea. Its structural formula is:
O
O
O
S
N
N
N
H
H
CH
3
C
15
H
21
N
3
O
3
S
Molecular weight: 323.4
Cas No.:
21187-98-4
DESCRIPTION
Gliclazide is a white or almost white powder, practically insoluble in water, freely soluble in
dichloromethane, sparingly soluble in acetone and slightly
soluble in ethanol 96%.
Nidem tablets contain
80 mg of gliclazide. The tablets also contain the following
excipients:
lactose, microcrystalline cellulose, povidone, purified talc, sodium
starch glycollate type A and
magnesium stearate. The tablets are gluten free.
PHARMACOLOGY
Mode of action: Gliclazide stimulates insulin secretion from
functional pancreatic beta-cells and
increases the sensitivity of the beta-cells to a glucose stimulus (some residual beta-cell function
is therefore necessary). Gliclazide restores the diminished first phase of insulin secretion noted in
non-insulin dependent diabetes mellitus.
Any
long-term hypoglycaemic activity of gliclazide can be attributed to an ability to maintain its
effect on insulin secretion. Extrapancreatic effects may also
be involved in the long-term efficacy
of gliclazide. Extrapancreatic effects demonstrated
for gliclazide include improvement in insulin
mediated glucose utilisation and
potentiation of postreceptor insulin sensitive pathways.
At normal therapeutic doses in humans, gliclazide reduces
platel
전체 문서 읽기